NGEN
NervGen Pharma Corp. Common stock (NGEN)
Healthcare • NASDAQ • $3.75-2.60%
- Symbol
- NGEN
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $3.75
- Daily Change
- -2.60%
- Market Cap
- $303.49M
- Trailing P/E
- N/A
- Forward P/E
- -9.88
- 52W High
- $6.30
- 52W Low
- $1.50
- Analyst Target
- $10.39
- Dividend Yield
- N/A
- Beta
- 0.88
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorp…
Company websiteResearch NGEN on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.